Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Surgical resection
15 evidence topics · 13 sources
Surgery for localized insulinoma: ENETS guidance
Cytoreductive surgery for advanced functioning tumors including insulinoma: ENETS guidance
Surgery and debulking for functioning pancreatic tumors including insulinoma: ESMO guideline
Resection of localized insulinoma: NANETS surgical guideline
“Resection of a localized insulinoma results in a 98% biochemical cure rate with a 6% chance of recurrence at 10 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the case of insulinoma, the morbidity associated with an extensive pancreatic mobilization and 10% risk of non-palpable or non-visible tumors outweigh the low-risk of malignancy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Therefore, surgical exploration or blind resection of the tail of the pancreas are not recommended.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with a localized, biochemically confirmed, functional PNET should be resected because clinical syndromes associated with each are significant, even when small in size. Furthermore, with the exception of insulinoma, the majority have significant malignant potential.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Criteria for selection of patients for enucleation have not been defined, but expert opinion suggests that enucleation should be reserved for smaller tumors, those more likely to display benign behavior (such as insulinomas or NF-PNETs <2 cm), and that are located >2–3 mm from the main pancreatic duct.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Surgery for benign and malignant insulinoma: JNETS guideline
“Surgery is generally recommended for insulinomas; when indicated, a minimally invasive approach is preferable [40, 41]. Pancreatectomy with lymphadenectomy is recommended for malignant insulinomas [42].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Curative resection and debulking for insulinoma: clinical review
“For single solitary insulinomas, curative surgical excision remains the treatment of choice. However, it should be performed only when the diagnosis is certain and by a surgeon who is skilled in pancreatic surgery.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Complications following pancreas resection include postoperative pancreatic fistula, postpancreatectomy hemorrhage, and delayed gastric emptying together with exocrine and endocrine pancreatic insufficiency.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In aggressive malignant cases, debulking of the panNEN, including locoregional lymph nodes can be considered on a case-by-case basis, particularly in an attempt to control the endogenous hyperinsulinemic hypoglycemia (54, 103, 118).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“If more than 90% of tumor load can be resected, palliative surgery can also be considered.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, most aggressive malignant metastatic insulinomas cannot be cured by surgery or ablation procedures alone and require supportive measures, medical antihormonal, and antitumor treatment (54).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Outcomes after enucleation and pancreatic resection of insulinoma in 198 patients
“A total of 198 patients (58.5% women; median age, 48 years) were identified.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Surgical procedures included 106 enucleations (54%) and 92 pancreatic resections (46%). Mortality was nil. Rate of clinically significant pancreatic fistula was 18%. Enucleations had a higher reoperation rate compared with pancreatic resections (8.5% vs 1%; P = .02).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median follow-up was 65 months. Six patients (3%; 5 patients had neuroendocrine tumors grade G2) developed tumor recurrence. Four patients (2%) died of disease. New exocrine (1.5%) and endocrine (4%) insufficiencies were associated only with pancreatic resections.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Perioperative morbidity of sporadic insulinoma resection over three decades
“Eighty patients underwent surgery for sporadic pancreatic insulinoma, 50 of which were female (62%), with a median age of 50 (36-70) years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The mortality rate was 6% (n = 5), with a morbidity rate of 72%, including 24 severe complications (30%) and 35 pancreatic fistulas (44%). No differences were found between formal pancreatectomy and PSP in terms of postoperative outcome procedures. The surgery was curative in all the patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Long-term cure after insulinoma resection at a referral center over two decades
“Sixty-one of 202 operated patients with pNEN had an insulinoma, 37 (61%) in group 1 and 24 (39%) in group 2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Enucleation was the most frequently performed operation (31 of 61, 51%), followed by distal resection (15 of 61, 25%) without significant differences between groups 1 and 2. The rate of relevant postoperative complications was not different between groups 1 and 2 (24% vs. 21%, p = 0.99). Two patients with benign insulinoma (1 out of each group) experienced disease recurrence and underwent a second resection. After a median follow-up of 134 (1–249) months, however, all 57 (100%) patients with benign insulinoma and 3 out of 4 patients with malignant insulinoma had no evidence of disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Minimally invasive versus open resection of insulinoma
“28 patients (37.8%) underwent an open approach, and 46 patients (62.2%) underwent an MIS approach.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Resection done by a MIS approach was associated with shorter length of stay (5.0 vs. 6.5 days, p = 0.011), fewer grade III/IV surgical complications (19.6% vs. 32.1%, p = 0.15), lower 30-day readmission rates (17.4% vs. 42.9%, p = 0.034), and no cases of incisional hernia (0% vs. 14.3%%, p = 0.018) within two years post-operatively. The difference in local recurrence rates was not statistically significant (4.3% vs. 3.6%, p = 1).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Long-term recurrence after insulinoma resection by MEN1 status
Survival with and without surgery in malignant insulinoma
“A total of 121 patients were identified.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Surgical resection was performed in 64% of patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“5-year OS was 84% and 14% for the surgery and no-surgery groups, respectively, p < 0.001.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“On multivariable analysis, surgical resection, male sex, and absence of metastatic disease were associated with greater overall and cancer-specific survival” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Surgical resection for NICTH: clinical review
“Once NICTH is identified and a primary tumor is found, the mainstay of treatment is surgical resection, which is curative for hypoglycemia if resection is complete (63–69). Resolution of hypoglycemia has also been described in cases of subtotal resection (70). In rare instances, hypoglycemia recurs with tumor recurrence after what was thought to be complete resection (71, 72). However, in many cases, total resection is either delayed or not feasible.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Surgical removal and recovery in IGF-2-mediated NICTH: systematic review of published cases
“Surgical removal was the most common treatment modality employed in 110 (47.2%) cases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Outcomes were available for 223 cases, and the overall recovery rate among all the participants was 77% (n = 172).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Surgery among recovered and deceased patients with IGF-2-mediated NICTH
| Treatment | Recovered (n = 172) | Died (n = 51) | p-value |
|---|---|---|---|
| Surgery | “95 (55.2%)”View highlighted excerpt for this quote | “15 (29.4%)”View highlighted excerpt for this quote | “.002”View highlighted excerpt for this quote |